Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) EBITDA Margin (2016 - 2020)

Historic EBITDA Margin for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Q2 2020 value amounting to 399.06%.

  • Avadel Pharmaceuticals' EBITDA Margin rose 4244100.0% to 399.06% in Q2 2020 from the same period last year, while for Mar 2021 it was 24.76%, marking a year-over-year increase of 160200.0%. This contributed to the annual value of 26.04% for FY2020, which is 667600.0% up from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported EBITDA Margin of 399.06% as of Q2 2020, which was up 4244100.0% from 53.07% recorded in Q1 2020.
  • Avadel Pharmaceuticals' 5-year EBITDA Margin high stood at 399.06% for Q2 2020, and its period low was 360.52% during Q4 2018.
  • Moreover, its 5-year median value for EBITDA Margin was 27.25% (2019), whereas its average is 7.71%.
  • Per our database at Business Quant, Avadel Pharmaceuticals' EBITDA Margin crashed by -50912500bps in 2016 and then soared by 4244100bps in 2020.
  • Over the past 5 years, Avadel Pharmaceuticals' EBITDA Margin (Quarter) stood at 39.61% in 2016, then crashed by -130bps to 11.74% in 2017, then tumbled by -2971bps to 360.52% in 2018, then skyrocketed by 81bps to 66.82% in 2019, then surged by 697bps to 399.06% in 2020.
  • Its EBITDA Margin was 399.06% in Q2 2020, compared to 53.07% in Q1 2020 and 66.82% in Q4 2019.